Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment
kowa-seisakusho.co.jp

See what CB Insights has to offer

Investments

1

Partners & Customers

1

About KOWA

KOWA (幸和製作所) (TYO: 7807) is a manufacturer of welfare nursing care products including walking cars and walking aids/walk assistance carts, silver cars, handrails, walking canes, bath related products, toilet related products and life-support products.

KOWA Headquarter Location

3-159-1, Kaisan-cho Sakai-ku

Sakai City, 590-0982,

Japan

+81-72-238-0459

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

KOWA Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KOWA Rank

Latest KOWA News

Insights on the Ophthalmic Instrumentation Global Market to 2027 - Featuring Kowa, Leica Microsystems and Nidek Among Others - ResearchAndMarkets.com

Sep 10, 2021

Amid the COVID-19 crisis, the global market for Ophthalmic Instrumentation estimated at US$7.1 Billion in the year 2020, is projected to reach a revised size of US$9.1 Billion by 2027, growing at a CAGR of 3.6% over the analysis period 2020-2027. Ophthalmic Disposables, one of the segments analyzed in the report, is projected to record a 3% CAGR and reach US$3.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ophthalmic Lasers segment is readjusted to a revised 4.4% CAGR for the next 7-year period. The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 6.4% CAGR The Ophthalmic Instrumentation market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 6.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR. OCT Systems Segment to Record 5.5% CAGR In the global OCT Systems segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$486 Million in the year 2020 will reach a projected size of US$678.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027, while Latin America will expand at a 6.6% CAGR through the analysis period. Select Competitors (Total 91 Featured): Abbott Medical Optics Inc. Ophthalmic Instrumentation - Market Snapshot Current and Future Analysis Ophthalmic Disease Statistics Cataract Treatment & Opportunities

KOWA Investments

1 Investments

KOWA has made 1 investments. Their latest investment was in Polaris as part of their Unattributed VC on September 9, 2018.

CBI Logo

KOWA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/28/2018

Unattributed VC

Polaris

$1.98M

Yes

2

Date

9/28/2018

Round

Unattributed VC

Company

Polaris

Amount

$1.98M

New?

Yes

Co-Investors

Sources

2

KOWA Partners & Customers

1 Partners and customers

KOWA has 1 strategic partners and customers. KOWA recently partnered with Chugai Pharmaceutical on November 11, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

11/15/2015

Partner

Chugai Pharmaceutical

Japan

CHUGAI PHARMACEUTICAL : Selective SGLT2 Inhibitor “DEBERZA ®â€ Enters a New Phase - License Agreement Expanded to Cover US and EU -

TOKYO and NAGOYA , November 9 , 2015 -- Chugai Pharmaceutical , Ltd. and Kowa Company , Ltd. announced today that both companies have agreed to expand the license agreement to include US and EU for Chugai Pharmaceutical 's original selective SGLT2 inhibitor , currently marketed by Kowa under the brand name ` DEBERZA ® tablets 20mg ' with the indication of type 2 diabetes in Japan .

1

Date

11/15/2015

Type

Partner

Business Partner

Chugai Pharmaceutical

Country

Japan

News Snippet

CHUGAI PHARMACEUTICAL : Selective SGLT2 Inhibitor “DEBERZA ®â€ Enters a New Phase - License Agreement Expanded to Cover US and EU -

TOKYO and NAGOYA , November 9 , 2015 -- Chugai Pharmaceutical , Ltd. and Kowa Company , Ltd. announced today that both companies have agreed to expand the license agreement to include US and EU for Chugai Pharmaceutical 's original selective SGLT2 inhibitor , currently marketed by Kowa under the brand name ` DEBERZA ® tablets 20mg ' with the indication of type 2 diabetes in Japan .

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.